Amarin Appeals FDA Ruling On Fish Oil Drug's Expansion

Law360, San Francisco (November 08, 2013, 6:10 PM ET) -- Amarin Corp. PLC on Thursday appealed a U.S. Food and Drug Administration panel's denial of expanded use of its fish oil drug Vascepa among adults with high cholesterol levels, saying in a federal filing that the denial would harm the company's financial condition.

In its quarterly report to the U.S. Securities and Exchange Commission, Amarin said that it is uncertain whether its appeal, in which it argues why it believes the FDA was wrong to rescind Vascepa's expansion, will be successful.

“There can be no assurance...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required